The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 33, No. 6, pp. 701-703. DOI 10.1345/aph.18249
© 1999 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fatemi, S.
Right arrow Articles by Kist, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fatemi, S.
Right arrow Articles by Kist, D.


Research Articles

Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression

SH Fatemi, ES Emamian, and DA Kist

OBJECTIVE: To report the therapeutic efficacy of venlafaxine and bupropion in a patient with treatment-refractory major depression. CASE SUMMARY: A 21-year-old white woman with chronic and recurrent major depression presented with lack of response to several antidepressants. On examination, the patient exhibited neurovegetative signs of depression, guilt feelings, and suicidal ideation. The patient was administered venlafaxine 75 mg three times daily. The dose was titrated to 150 mg three times daily over the next month. Later bupropion was instituted up to 100 mg three times daily over a four-month period. The patient responded favorably to combination therapy and has remained free of depression for approximately 23 months. DISCUSSION: Venlafaxine and bupropion are antidepressant agents with unique pharmacologic profiles, each effective in the treatment of depression. Recent data indicate that combinations of selective serotonin-reuptake inhibitors and bupropion can convert partial response to full response in patients with treatment-resistant depression. We considered whether a combination of venlafaxine and bupropion would reduce the depressive symptoms of a patient who was unresponsive to various classes of psychotropic agents. Gradual administration of venlafaxine and bupropion acted synergistically to significantly reduce depressive symptoms (p < 0.002) and significantly increase social function (p < 0.002) over a period of eight months. CONCLUSIONS: To our knowledge this is the first report of successful combination therapy with venlafaxine and bupropion in treatment of chronic recurrent and refractory major depression.


This article has been cited by other articles:


Home page
ANN INTERN MEDHome page
R. A. Mahmoud, G. J. Pandina, I. Turkoz, C. Kosik-Gonzalez, C. M. Canuso, M. J. Kujawa, and G. M. Gharabawi-Garibaldi
Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial
Ann Intern Med, November 6, 2007; 147(9): 593 - 602.
[Abstract] [Full Text] [PDF]


Home page
Psychiatr. Serv.Home page
R. C. Shelton and A. J. Tomarken
Can Recovery From Depression Be Achieved?
Psychiatr Serv, November 1, 2001; 52(11): 1469 - 1478.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1999 by Harvey Whitney Books Company.